Rytary (IPX066) vs TR-012001
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Parkinson's Disease
Shared mechanism: dopamine precursor · full Parkinson's Disease pipeline
Rytary (IPX066)
Marketed by Amneal Pharmaceuticals
NCT00974974 · Phase 3 · completed
This was a randomized, quadruple-blind, active-controlled phase 3 trial with 393 randomized participants. The primary clinical endpoint—percentage of waking hours spent in the Parkinsonian “off” state—favored IPX066 over immediate-release carbidopa-levodopa and was statistically significant (p<0.0001).
Reported efficacy
Percentage of "Off" Time During Waking Hours at End of Study (22 weeks): Percentage of "Off" Time During Waking Hours at End of Study (22 weeks): IPX066 23.82 percentage (Standard Deviation 14.91) vs IR CD-LD (Active Comparator) 29.79 percentage (Standard Deviation 15.81) (met)
Result source: NCT00974974
TR-012001
Developed by SNLD, Ltd.
NCT06212089 · Phase 2 · completed
The study randomly assigned 12 Japanese patients with Parkinson's disease to one nasal dose of TR-012001 or placebo, single-blind. Its registered primary outcomes were safety measures, so there is no efficacy comparison to call. The AAN 2025 abstract reports that all adverse drug reactions were mild, transient nasal reactions and that 8 of 9 treated patients reached peak plasma levodopa within 15 minutes. The study is very small and tested a single dose.
Conference abstract (AAN 2025); not peer reviewed and not posted on ClinicalTrials.gov.
Reported efficacy
Safety evaluation of TR-012001: Incidents of Treatment-Emergent Adverse Events (Day of administration of TR-012001/placebo (Day3) to the day of leaving the facility (Day4). If any adverse event(s) continue or occur on Day4, follow-up will be conducted until recovery or until the investigator decides no longer follow-up is necessary.); Safety evaluation of TR-012001: Incidents of physical findings (4 days and 3 nights); Safety evaluation of TR-012001: Vital sign (body temperature) (4 days and 3 nights); Safety evaluation of TR-012001: Vital sign (blood pressure) (4 days and 3 nights); Safety evaluation of TR-012001: Vital sign (pulse rate) (4 days and 3 nights); Safety evaluation of TR-012001: Columbia Suicide Severity Rating Scale (C-SSRS) (Day 1 and Day 4); Safety evaluation of TR-012001: Incidents of participants with laboratory abnormality (Day 1 and Day 4); Pharmacokinetics of TR-012001: Maximum plasma concentration (Cmax) (Pre-dose (baseline) and specified time points of post-dose); Pharmacokinetics of TR-012001: Time to reach maximum plasma concentration (Tmax) (Pre-dose (baseline) and specified time points of post-dose); Pharmacokinetics of TR-012001: Elimination half-life (t1/2) (Pre-dose (baseline) and specified time points of post-dose); Pharmacokinetics of TR-012001: Area under the plasma concentration-time curve (AUC0-inf) (Pre-dose (baseline) and specified time points of post-dose); Pharmacokinetics of TR-012001: Mean residence time (MRT) (Pre-dose (baseline) and specified time points of post-dose); Pharmacokinetics of TR-012001: Apparent whole body clearance (CL/f) (Pre-dose (baseline) and specified time points of post-dose); Pharmacokinetics of TR-012001: Volume of distribution (Vd/f ) (Pre-dose (baseline) and specified time points of post-dose): Single nasal dose in 12 patients (9 TR-012001, total levodopa 40 mg; 3 placebo): all adverse drug reactions were mild and transient nasal administration reactions, and all 12 patients completed. 8 of 9 TR-012001 patients reached peak plasma levodopa within 15 minutes of dosing. (not_applicable)
Result source: NCT06212089
Results for Parkinson's Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Rytary (IPX066) | TR-012001 |
|---|---|---|
| OFF time, change | —Not reported | —Not reported |
| ON time without troublesome dyskinesia, change | —Not reported | —Not reported |
| UPDRS Part III, change | 21.6 vs 25.5vs IR CD-LDNCT00869791 | —Not reported |
| MDS-UPDRS Part II, change | —Not reported | —Not reported |
OFF time, change
- Rytary (IPX066)
- —Not reported
- TR-012001
- —Not reported
ON time without troublesome dyskinesia, change
- Rytary (IPX066)
- —Not reported
- TR-012001
- —Not reported
UPDRS Part III, change
- Rytary (IPX066)
- 21.6 vs 25.5vs IR CD-LDNCT00869791
- TR-012001
- —Not reported
MDS-UPDRS Part II, change
- Rytary (IPX066)
- —Not reported
- TR-012001
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
TR-012001: no structured comparison results are available for Parkinson's Disease.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Rytary (IPX066): 4 of 4 rows · TR-012001: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Rytary (IPX066) |
|---|---|
| Dropout rate | —a NCT00974974 · Phase 3 · combination · Parkinson's Disease · phase 3 show 9 more results24.5%390 mg LD NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3 20.2%245 mg LD NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3 17.2%145 mg LD NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3 —Part 1: Conversion NCT01411137 · Phase 3 · registry result, not featured evidence —Part 2: Open-Label Extension 1 NCT01411137 · Phase 3 · registry result, not featured evidence —Part 3: Open-Label Extension 2 NCT01411137 · Phase 3 · registry result, not featured evidence — NCT01130493 · Phase 3 · registry result, not featured evidence 8.1% NCT01096186 · Phase 3 · registry result, not featured evidence — NCT00869791 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | —a NCT00974974 · Phase 3 · combination · Parkinson's Disease · phase 3 show 9 more results15.3%390 mg LD NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3 14.4%245 mg LD NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3 5.7%145 mg LD NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3 —Part 1: Conversion NCT01411137 · Phase 3 · registry result, not featured evidence —Part 2: Open-Label Extension 1 NCT01411137 · Phase 3 · registry result, not featured evidence —Part 3: Open-Label Extension 2 NCT01411137 · Phase 3 · registry result, not featured evidence — NCT01130493 · Phase 3 · registry result, not featured evidence 2.6% NCT01096186 · Phase 3 · registry result, not featured evidence — NCT00869791 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 5.5%a NCT00974974 · Phase 3 · combination · Parkinson's Disease · phase 3 show 9 more results2%390 mg LD NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3 4.8%245 mg LD NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3 4.6%145 mg LD NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3 2.3%Part 1: Conversion NCT01411137 · Phase 3 · registry result, not featured evidence 15.6%Part 2: Open-Label Extension 1 NCT01411137 · Phase 3 · registry result, not featured evidence 25%Part 3: Open-Label Extension 2 NCT01411137 · Phase 3 · registry result, not featured evidence 1.1% NCT01130493 · Phase 3 · registry result, not featured evidence 7% NCT01096186 · Phase 3 · registry result, not featured evidence 0% NCT00869791 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | show 9 more results390 mg LD nausea 20.4% (placebo 8.7%) headache 17.3% (placebo 10.9%) dizziness 12.2% (placebo 5.4%) NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3 245 mg LD dizziness 19.2% (placebo 5.4%) nausea 19.2% (placebo 8.7%) headache 12.5% (placebo 10.9%) NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3 145 mg LD nausea 13.8% (placebo 8.7%) dizziness 9.2% (placebo 5.4%) headache 6.9% (placebo 10.9%) NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3 upper respiratory infection 15.6% anxiety 6.3% fall 6.3% NCT01411137 · Phase 3 · registry result, not featured evidence fall 16.7% orthostatic hypotension 16.7% anxiety 8.3% NCT01411137 · Phase 3 · registry result, not featured evidence dyskinesia 4.5% confusional state 3.4% insomnia 3.4% NCT01130493 · Phase 3 · registry result, not featured evidence anxiety 3.7% fatigue 3.7% feeling of warth in abdomen 3.7% NCT00869791 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 6 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Rytary (IPX066)
show 2 more results
show 1 more result
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 3 more results
+ 4 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Rytary (IPX066)'s landscape · TR-012001's landscape